AAP
RCEL icon

Arax Advisory Partners’s Avita Medical RCEL Stock Holding History

Arax Advisory Partners’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111 Buy
30
+20
+200% +$84 ﹤0.01% 3604
2025
Q4 		$35 Sell
10
-431
-98% -$1.72K ﹤0.01% 3976
2025
Q3 		$2.25K Buy
+441
New +$2.3K ﹤0.01% 3090

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arax Advisory Partners's RCEL Position: Q1 2026 in Review

Arax Advisory Partners increased its Avita Medical (RCEL) stake by 200% in Q1 2026, buying an estimated $84 and bringing the position to 30 shares worth $111. The position accounts for ﹤0.01% of the portfolio, ranked #3604.

Arax Advisory Partners first reported a position in RCEL in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.25K in Q3 2025. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Arax Advisory Partners held 30 shares of Avita Medical worth $111 as of Q1 2026.
  • Arax Advisory Partners bought 20 Avita Medical shares in Q1 2026, an estimated $84.
  • Avita Medical made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3604 holding.
  • Arax Advisory Partners first reported a position in Avita Medical in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Avita Medical position peaked at $2.25K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.